Eeva-Kaisa Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eeva-Kaisa Schmidt has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Sari Atula
Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, HYKS, Tornisairaala, Neupkl, Haartmaninkatu 4, 00029 HUS, Helsinki, Finland
4 shared publicationsSari Kiuru-Enari
Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, HYKS, Tornisairaala, Neupkl, Haartmaninkatu 4, 00029 HUS, Helsinki, Finland
4 shared publicationsMaarit Tanskanen
C Department of Pathology, HUSLAB, Helsinki University Hospital , Helsinki , Finland
2 shared publicationsTuuli Mustonen
Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, HYKS, Tornisairaala, Neupkl, Haartmaninkatu 4, 00029 HUS, Helsinki, Finland
2 shared publicationsIrma-Leena Notkola
D The National Archives , Helsinki , Finland
1 shared publication- Juha Kere
Stem Cells and Metabolism Research Program, University of Helsinki, Helsinki, Finland
1 shared publication
Latest Publications
- Open Access
Tracing the origin of Finnish gelsolin amyloidosis using haplotype sharing trees
Finnish gelsolin amyloidosis (AGel amyloidosis) is an autosomal dominant systemic amyloidosis caused by GSN c.640G>A p.D187N (rs121909715) founder variant. The disease was first described in 1969, and it was hypothesized that the Finnish patients share a common ancestor dating back to the 14th century. The link between two Finnish regions with high AGel incidence (Kanta-Häme and Kymenlaakso) has been hypothesized to have occurred in 1365 by a settler moving from Kanta-Häme to Kymenlaakso. Here, we used haplotype sharing tree (HST) to analyze Finnish AGel amyloidosis haplotypes to trace the geographic origin of the variant. We also estimated the time from the most recent common ancestor (MRCA) using single nucleotide polymorphism and short tandem repeat data. The HST -based analyses leveraging AGel amyloidosis cohorts from different Finnish geographic regions indicated, that the variant more likely appeared first in Kymenlaakso, not Kanta-Häme, contrary to the original hypothesis. The MRCA estimates for Finnish AGel ranged from 15 to 40 generations using four different methods, the mean of all estimates (27 generations) dated back to the 14th century. Thus, the data supports the original hypothesis on the variant’s spreading temporally, but not geographically. These results illustrate the use of HSTs in the analysis of haplotype structures and in tracing the ancestry of a founder variant.
Open AccessTracing the origin of Finnish gelsolin amyloidosis using haplotype sharing trees
Finnish gelsolin amyloidosis (AGel amyloidosis) is an autosomal dominant systemic amyloidosis caused by GSN c.640G>A p.D187N (rs121909715) founder variant. The disease was first described in 1969, and it was hypothesized that the Finnish patients share a common ancestor dating back to the 14th century. The link between two Finnish regions with high AGel incidence (Kanta-Häme and Kymenlaakso) has been hypothesized to have occurred in 1365 by a settler moving from Kanta-Häme to Kymenlaakso. Here, we used haplotype sharing tree (HST) to analyze Finnish AGel amyloidosis haplotypes to trace the geographic origin of the variant. We also estimated the time from the most recent common ancestor (MRCA) using single nucleotide polymorphism and short tandem repeat data. The HST -based analyses leveraging AGel amyloidosis cohorts from different Finnish geographic regions indicated, that the variant more likely appeared first in Kymenlaakso, not Kanta-Häme, contrary to the original hypothesis. The MRCA estimates for Finnish AGel ranged from 15 to 40 generations using four different methods, the mean of all estimates (27 generations) dated back to the 14th century. Thus, the data supports the original hypothesis on the variant’s spreading temporally, but not geographically. These results illustrate the use of HSTs in the analysis of haplotype structures and in tracing the ancestry of a founder variant.
- Open Access
- 17 January 2020
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 15 (1) , 1-13
Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study
Background: Hereditary gelsolin (AGel) amyloidosis is an autosomal dominantly inherited systemic amyloidosis that manifests with the characteristic triad of progressive ophthalmological, neurological and dermatological signs and symptoms. The National Finnish Gelsolin Amyloidosis Registry (FIN-GAR) was founded in 2013 to collect clinical data on patients with AGel amyloidosis, including altogether approximately one third of the Finnish patients. We aim to deepen knowledge on the disease burden and life span of the patients using data from the updated FIN-GAR registry. We sent an updated questionnaire concerning the symptoms and signs, symptomatic treatments and subjective perception on disease progression to 240 members of the Finnish Amyloidosis Association (SAMY). We analyzed the lifespan of 478 patients using the relative survival (RS) framework. Results: The updated FIN-GAR registry includes 261 patients. Symptoms and signs corresponding to the classical triad of ophthalmological (dry eyes in 93%; corneal lattice amyloidosis in 89%), neurological (numbness, tingling and other paresthesias in 75%; facial paresis in 67%), and dermatological (drooping eyelids in 86%; cutis laxa in 84%) manifestations were highly prevalent. Cardiac arrhythmias were reported by 15% of the patients and 5% had a cardiac pacemaker installed. Proteinuria was reported by 13% and renal failure by 5% of the patients. A total of 65% of the patients had undergone a skin or soft tissue surgery, 26% carpal tunnel surgery and 24% at least unilateral cataract surgery. As regards life span, relative survival estimates exceeded 1 for males and females until the age group of 70–74 years, for which it was 0.96. Conclusions: AGel amyloidosis causes a wide variety of ophthalmological, neurological, cutaneous, and oral symptoms that together with repeated surgeries cause a clinically significant disease burden. Severe renal and cardiac manifestations are rare as compared to other systemic amyloidoses, explaining in part the finding that AGel amyloidosis does not shorten the life span of the patients at least for the first 75 years.
- 17 January 2020
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 15 (1) , 1-13
Open AccessFinnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study
Background: Hereditary gelsolin (AGel) amyloidosis is an autosomal dominantly inherited systemic amyloidosis that manifests with the characteristic triad of progressive ophthalmological, neurological and dermatological signs and symptoms. The National Finnish Gelsolin Amyloidosis Registry (FIN-GAR) was founded in 2013 to collect clinical data on patients with AGel amyloidosis, including altogether approximately one third of the Finnish patients. We aim to deepen knowledge on the disease burden and life span of the patients using data from the updated FIN-GAR registry. We sent an updated questionnaire concerning the symptoms and signs, symptomatic treatments and subjective perception on disease progression to 240 members of the Finnish Amyloidosis Association (SAMY). We analyzed the lifespan of 478 patients using the relative survival (RS) framework. Results: The updated FIN-GAR registry includes 261 patients. Symptoms and signs corresponding to the classical triad of ophthalmological (dry eyes in 93%; corneal lattice amyloidosis in 89%), neurological (numbness, tingling and other paresthesias in 75%; facial paresis in 67%), and dermatological (drooping eyelids in 86%; cutis laxa in 84%) manifestations were highly prevalent. Cardiac arrhythmias were reported by 15% of the patients and 5% had a cardiac pacemaker installed. Proteinuria was reported by 13% and renal failure by 5% of the patients. A total of 65% of the patients had undergone a skin or soft tissue surgery, 26% carpal tunnel surgery and 24% at least unilateral cataract surgery. As regards life span, relative survival estimates exceeded 1 for males and females until the age group of 70–74 years, for which it was 0.96. Conclusions: AGel amyloidosis causes a wide variety of ophthalmological, neurological, cutaneous, and oral symptoms that together with repeated surgeries cause a clinically significant disease burden. Severe renal and cardiac manifestations are rare as compared to other systemic amyloidoses, explaining in part the finding that AGel amyloidosis does not shorten the life span of the patients at least for the first 75 years.
- 23 May 2019
- Published by Taylor & Francis in Amyloid
- Vol. 26 (3) , 118-124
Amyloid in parenchymal organs in gelsolin (AGel) amyloidosis
Objectives: Previous clinical studies have shown frequent cardiac symptoms in patients with hereditary gelsolin (AGel) amyloidosis, possibly related to amyloid deposition in the heart and other internal organs. Previous studies on internal organ amyloid deposition in AGel amyloidosis have been based on small patient series. Methods: Paraffin-embedded tissue sections from 25 autopsied individuals (age at death 44.4–88.6 years) with AGel amyloidosis were stained with HE, Congo red and Herovici stains and immunohistochemistry against the low molecular weight gelsolin fraction was performed. The amount of amyloid was estimated semi-quantitatively. Results: AGel-based amyloid deposits were found in the myocardium and cardiac blood vessels in every patient. The deposits were mainly small and co-localized with regions with excess fibrosis in the myocardium. The lungs were positive for amyloid in 79%, renal parenchyma in 54% and renal blood vessels in 71% of the cases. The amount of myocardial, renal and hepatic amyloid correlated with age at death of the patients. Conclusions: We show the constant presence of AGel amyloid in the hearts of patients with AGel amyloidosis. Although the deposits were mainly small, the co-localization of amyloid with fibrosis may amplify the effect of pure amyloid deposition, possibly leading to clinical signs and symptoms.
- 23 May 2019
- Published by Taylor & Francis in Amyloid
- Vol. 26 (3) , 118-124
Amyloid in parenchymal organs in gelsolin (AGel) amyloidosis
Objectives: Previous clinical studies have shown frequent cardiac symptoms in patients with hereditary gelsolin (AGel) amyloidosis, possibly related to amyloid deposition in the heart and other internal organs. Previous studies on internal organ amyloid deposition in AGel amyloidosis have been based on small patient series. Methods: Paraffin-embedded tissue sections from 25 autopsied individuals (age at death 44.4–88.6 years) with AGel amyloidosis were stained with HE, Congo red and Herovici stains and immunohistochemistry against the low molecular weight gelsolin fraction was performed. The amount of amyloid was estimated semi-quantitatively. Results: AGel-based amyloid deposits were found in the myocardium and cardiac blood vessels in every patient. The deposits were mainly small and co-localized with regions with excess fibrosis in the myocardium. The lungs were positive for amyloid in 79%, renal parenchyma in 54% and renal blood vessels in 71% of the cases. The amount of myocardial, renal and hepatic amyloid correlated with age at death of the patients. Conclusions: We show the constant presence of AGel amyloid in the hearts of patients with AGel amyloidosis. Although the deposits were mainly small, the co-localization of amyloid with fibrosis may amplify the effect of pure amyloid deposition, possibly leading to clinical signs and symptoms.
- Open Access
- 22 November 2017
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 26 (1) , 117-123
Common origin of the gelsolin gene variant in 62 Finnish AGel amyloidosis families
Finnish gelsolin amyloidosis (AGel amyloidosis) is an autosomal dominantly inherited systemic disorder with ophthalmologic, neurologic and dermatologic symptoms. Only the gelsolin (GSN) c.640G>A variant has been found in the Finnish patients thus far. The purpose of this study was to examine whether the Finnish patients have a common ancestor or whether multiple mutation events have occurred at c.640G, which is a known mutational hot spot. A total of 79 Finnish AGel amyloidosis families including 707 patients were first discovered by means of patient interviews, genealogic studies and civil and parish registers. From each family 1-2 index patients were chosen. Blood samples were available from 71 index patients representing 64 families. After quality control, SNP array genotype data were available from 68 patients from 62 nuclear families. All the index patients had the same c.640G>A variant (rs121909715). Genotyping was performed using the Illumina CoreExome SNP array. The homozygosity haplotype method was used to analyse shared haplotypes. Haplotype analysis identified a shared haplotype, common to all studied patients. This shared haplotype included 17 markers and was 361 kb in length (GRCh37 coordinates 9:124003326–124364349) and this level of haplotype sharing was found to occur highly unlikely by chance. This GSN haplotype ranked as the largest shared haplotype in the 68 patients in a genome-wide analysis of haplotype block lengths. These results provide strong evidence that although there is a known mutational hot spot at GSN c.640G, all of the studied 62 Finnish AGel amyloidosis families are genetically linked to a common ancestor.
- 22 November 2017
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 26 (1) , 117-123
Open AccessCommon origin of the gelsolin gene variant in 62 Finnish AGel amyloidosis families
Finnish gelsolin amyloidosis (AGel amyloidosis) is an autosomal dominantly inherited systemic disorder with ophthalmologic, neurologic and dermatologic symptoms. Only the gelsolin (GSN) c.640G>A variant has been found in the Finnish patients thus far. The purpose of this study was to examine whether the Finnish patients have a common ancestor or whether multiple mutation events have occurred at c.640G, which is a known mutational hot spot. A total of 79 Finnish AGel amyloidosis families including 707 patients were first discovered by means of patient interviews, genealogic studies and civil and parish registers. From each family 1-2 index patients were chosen. Blood samples were available from 71 index patients representing 64 families. After quality control, SNP array genotype data were available from 68 patients from 62 nuclear families. All the index patients had the same c.640G>A variant (rs121909715). Genotyping was performed using the Illumina CoreExome SNP array. The homozygosity haplotype method was used to analyse shared haplotypes. Haplotype analysis identified a shared haplotype, common to all studied patients. This shared haplotype included 17 markers and was 361 kb in length (GRCh37 coordinates 9:124003326–124364349) and this level of haplotype sharing was found to occur highly unlikely by chance. This GSN haplotype ranked as the largest shared haplotype in the 68 patients in a genome-wide analysis of haplotype block lengths. These results provide strong evidence that although there is a known mutational hot spot at GSN c.640G, all of the studied 62 Finnish AGel amyloidosis families are genetically linked to a common ancestor.
- 2 May 2016
- Published by Taylor & Francis in Annals of Medicine
- Vol. 48 (5) , 352-358
Causes of death and life span in Finnish gelsolin amyloidosis
Background: Finnish type of hereditary gelsolin amyloidosis (AGel amyloidosis) is an autosomal dominant disorder. Until recently, there has only been little knowledge of fatal complications of the disease and its possible impact on the patients’ life span. Methods: We identified 272 deceased patients based on patient interviews and genealogical data. After collecting their death certificates, we recorded the patients’ underlying and immediate causes of death (CoD) and life span and compared them to the general Finnish population. We then calculated proportional mortality ratios (PMR), standardised for age and sex, for the CoDs. Results: The underlying CoD in 20% of the patients was AGel amyloidosis (PMR = 114.2; 95% CI: 85.6–149.4). The frequency of fatal cancers (10%) was significantly diminished (PMR = 0.47; 95% CI: 0.31–0.69). Renal complications were overrepresented as the immediate CoD in female patients (PMR = 2.82 95% CI: 1.13–5.81). The mean life span for male patients was 73.9 years (95% CI: 72.0–75.6) and 78.0 years for female patients (95% CI: 76.4–79.5) compared to 72.1 and 80.1 years for the general population. Conclusions: Our results suggest that the disease increases the risk of fatal renal complications but does not substantially shorten the life span, possibly due to the significantly lower frequency of fatal cancers.
- 2 May 2016
- Published by Taylor & Francis in Annals of Medicine
- Vol. 48 (5) , 352-358
Causes of death and life span in Finnish gelsolin amyloidosis
Background: Finnish type of hereditary gelsolin amyloidosis (AGel amyloidosis) is an autosomal dominant disorder. Until recently, there has only been little knowledge of fatal complications of the disease and its possible impact on the patients’ life span. Methods: We identified 272 deceased patients based on patient interviews and genealogical data. After collecting their death certificates, we recorded the patients’ underlying and immediate causes of death (CoD) and life span and compared them to the general Finnish population. We then calculated proportional mortality ratios (PMR), standardised for age and sex, for the CoDs. Results: The underlying CoD in 20% of the patients was AGel amyloidosis (PMR = 114.2; 95% CI: 85.6–149.4). The frequency of fatal cancers (10%) was significantly diminished (PMR = 0.47; 95% CI: 0.31–0.69). Renal complications were overrepresented as the immediate CoD in female patients (PMR = 2.82 95% CI: 1.13–5.81). The mean life span for male patients was 73.9 years (95% CI: 72.0–75.6) and 78.0 years for female patients (95% CI: 76.4–79.5) compared to 72.1 and 80.1 years for the general population. Conclusions: Our results suggest that the disease increases the risk of fatal renal complications but does not substantially shorten the life span, possibly due to the significantly lower frequency of fatal cancers.